HIT! High Impact Clinical Trials – What and Why

7 Feb 2025 2:15 p.m. 3:45 p.m.

Brahmkamal Hall - Plenary Hall

Andrea Vichelli Chair AustraliaUniversity of Queensland

VivekKumar Chair IndiaPostgraduate Institute of Medical Education and Research, Chandigarh, India

Time	Session

2:15 p.m. 2:45 p.m.	Combination Effect of Finerenone and Empagliflozin in Participants With Chronic Kidney Disease and Type 2 Diabetes Using a UACR Endpoint Study (CONFIDENCE) HIT1-1 RajivAgarwal Oral Abstract Presenter ragarwal@iu.eduUnited States
2:45 p.m. 3:15 p.m.	Results From the REGENCY Trial Assessing Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis HIT1-2 BradRovin Oral Abstract Presenter rovin.1@osu.eduUnited StatesThe Ohio State University
3:15 p.m. 3:45 p.m.	Clinical and Safety Outcomes of Semaglutide by CKD Severity in the FLOW trial HIT1-3 KatherineTuttle Oral Abstract Presenter Katherine.Tuttle@providence.orgUnited StatesUniversity of Washington School of Medicine, Division of Nephrology